TriClip Transcatheter Edge-to-Edge Repair (TEER) System
Category: Analytical/Test
Developers: Abbott
Product Description:Abbott’s TriClip transcatheter edge-to-edge repair system is a minimally invasive device designed for the heart’s difficult-to-treat tricuspid valve. It could offer a safe and effective solution for patients suffering from severe tricuspid regurgitation (a leaky tricuspid valve) without the need for open-heart surgery. Approximately 1.6 million people in the U.S. and more than 70 million globally currently live with moderate or severe tricuspid regurgitation (TR), for which there are few treatment options. TR patients have long faced limited, high-risk treatment options, such as surgery or medical therapy, leaving them with debilitating and potentially life-threatening consequences. Abbott developed the minimally invasive TriClip TEER system to fill this critical treatment gap. TriClip is reportedly the first non-surgical repair option for patients who don’t respond to traditional therapies and aren’t candidates for surgery. TriClip is specifically designed to treat the tricuspid valve’s complex anatomy and help restore tricuspid valve performance without subjecting patients with TR to high-risk open-heart surgery. It could offer a safer path to relief from TR and reduces symptoms of fatigue, swelling and shortness of breath.
Developers: Abbott
Product Description:Abbott’s TriClip transcatheter edge-to-edge repair system is a minimally invasive device designed for the heart’s difficult-to-treat tricuspid valve. It could offer a safe and effective solution for patients suffering from severe tricuspid regurgitation (a leaky tricuspid valve) without the need for open-heart surgery. Approximately 1.6 million people in the U.S. and more than 70 million globally currently live with moderate or severe tricuspid regurgitation (TR), for which there are few treatment options. TR patients have long faced limited, high-risk treatment options, such as surgery or medical therapy, leaving them with debilitating and potentially life-threatening consequences. Abbott developed the minimally invasive TriClip TEER system to fill this critical treatment gap. TriClip is reportedly the first non-surgical repair option for patients who don’t respond to traditional therapies and aren’t candidates for surgery. TriClip is specifically designed to treat the tricuspid valve’s complex anatomy and help restore tricuspid valve performance without subjecting patients with TR to high-risk open-heart surgery. It could offer a safer path to relief from TR and reduces symptoms of fatigue, swelling and shortness of breath.
